Market Cap 1.69B
Revenue (ttm) 63.52M
Net Income (ttm) -376.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -593.10%
Debt to Equity Ratio 0.00
Volume 871,097
Avg Vol 2,039,726
Day's Range N/A - N/A
Shares Out 100.56M
Stochastic %K 18%
Beta 2.08
Analysts Strong Sell
Price Target $45.80

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 327 8775
Website: beamtx.com
Address:
238 Main Street, Cambridge, United States
NapoleonOfFinance
NapoleonOfFinance Jun. 23 at 12:39 PM
$BEAM buy beam
0 · Reply
FinJay
FinJay Jun. 19 at 12:17 AM
$BEAM https://youtu.be/A7w3ID9abp8
0 · Reply
BernhardtA19
BernhardtA19 Jun. 18 at 10:17 PM
$BEAM $LLY gobbled $VERV. Seems like LNP delivered base editors to the liver have been somewhat de-risked. Wonder if another big boy (ahem, Pfizer) will take a shot with $BEAM in a similar fashion. The race is on???
2 · Reply
NapoleonOfFinance
NapoleonOfFinance Jun. 18 at 2:01 PM
$BEAM buy buy buy!
0 · Reply
Recoverymad
Recoverymad Jun. 18 at 1:52 PM
$NTLA $BEAM $CRSP about to be a nice run. Appropriate risk reward in a de-reg environment with other sectors at tippy top
1 · Reply
DNAedit
DNAedit Jun. 17 at 6:25 PM
$VERV based on $BEAM technology. Beam sold the right for this one treatment to Eli but they will cure a lot more!
0 · Reply
biotech
biotech Jun. 17 at 2:42 PM
$SGMO related: $LLY $VERV buyout Bernstein says not especially optimistic that either $NTLA or $BEAM would be acquired This is a deal #only LLY could do early stage, and LLY have de-risked this through 2-collaborations value seems balanced considering cash/prior milestones $LLY had made
0 · Reply
jac05010
jac05010 Jun. 17 at 2:20 PM
$BEAM $EDIT $NTLA $PRME $SGMO because SGMO is a joke. Who would want to park their money here? All the pumping on X is just that- pumping. Market is trying to tell us something- get out
1 · Reply
paleogos
paleogos Jun. 17 at 1:19 PM
$SGMO $PRME +20%, $NTLA +14%, $BEAM +7%, $EDIT +7%...Sandy weighs on this stock like an anchor
0 · Reply
prismmarketview
prismmarketview Jun. 16 at 2:07 PM
$BEAM https://prismmarketview.com/beam-posts-new-sickle-cell-data-from-beam-101-study-patients-show-strong-response-with-minimal-burden/
0 · Reply
Latest News on BEAM
Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:01 AM EDT - 3 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering


Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 11:54 AM EST - 8 months ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript


CRISPR Gene Editing: Beam Therapeutics

Nov 30, 2023, 4:36 AM EST - 1 year ago

CRISPR Gene Editing: Beam Therapeutics


NapoleonOfFinance
NapoleonOfFinance Jun. 23 at 12:39 PM
$BEAM buy beam
0 · Reply
FinJay
FinJay Jun. 19 at 12:17 AM
$BEAM https://youtu.be/A7w3ID9abp8
0 · Reply
BernhardtA19
BernhardtA19 Jun. 18 at 10:17 PM
$BEAM $LLY gobbled $VERV. Seems like LNP delivered base editors to the liver have been somewhat de-risked. Wonder if another big boy (ahem, Pfizer) will take a shot with $BEAM in a similar fashion. The race is on???
2 · Reply
NapoleonOfFinance
NapoleonOfFinance Jun. 18 at 2:01 PM
$BEAM buy buy buy!
0 · Reply
Recoverymad
Recoverymad Jun. 18 at 1:52 PM
$NTLA $BEAM $CRSP about to be a nice run. Appropriate risk reward in a de-reg environment with other sectors at tippy top
1 · Reply
DNAedit
DNAedit Jun. 17 at 6:25 PM
$VERV based on $BEAM technology. Beam sold the right for this one treatment to Eli but they will cure a lot more!
0 · Reply
biotech
biotech Jun. 17 at 2:42 PM
$SGMO related: $LLY $VERV buyout Bernstein says not especially optimistic that either $NTLA or $BEAM would be acquired This is a deal #only LLY could do early stage, and LLY have de-risked this through 2-collaborations value seems balanced considering cash/prior milestones $LLY had made
0 · Reply
jac05010
jac05010 Jun. 17 at 2:20 PM
$BEAM $EDIT $NTLA $PRME $SGMO because SGMO is a joke. Who would want to park their money here? All the pumping on X is just that- pumping. Market is trying to tell us something- get out
1 · Reply
paleogos
paleogos Jun. 17 at 1:19 PM
$SGMO $PRME +20%, $NTLA +14%, $BEAM +7%, $EDIT +7%...Sandy weighs on this stock like an anchor
0 · Reply
prismmarketview
prismmarketview Jun. 16 at 2:07 PM
$BEAM https://prismmarketview.com/beam-posts-new-sickle-cell-data-from-beam-101-study-patients-show-strong-response-with-minimal-burden/
0 · Reply
DeerHunter55
DeerHunter55 Jun. 16 at 1:49 PM
$NTLA $CRSP $EDIT $BEAM $CRBU https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-positive-three-year-data-phase-1
0 · Reply
StockAnalyticsAI
StockAnalyticsAI Jun. 14 at 7:10 PM
$BEAM Deep Dive https://youtu.be/dez-g1VSbGU?si=MdEQxb1Orlh2oPey
0 · Reply
Ebrice73
Ebrice73 Jun. 14 at 4:42 AM
$BEAM awesome! Looking solid. Hopefully it does not fly to $50 Monday. Ready to load if that door stays open.
1 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 13 at 12:21 PM
$BEAM Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress By
0 · Reply
DonCorleone77
DonCorleone77 Jun. 13 at 11:04 AM
$BEAM Beam Therapeutics announces new data from BEACON Phase 1/2 trial Beam Therapeutics announces new safety and efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease with severe vaso-occlusive crises. The data will be shared in a poster presentation today at the European Hematology Association 2025 Congress in Milan. New data from the BEACON trial with more patients and longer follow-up provide further demonstration of the strong clinical profile for the investigational base-editing therapy BEAM-101, as initially established in previously announced data at the 66th American Society of Hematology Annual Meeting and Exposition in December 2024. Updated data from 17 patients treated with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin and reductions in sickle hemoglobin, rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis and oxygen delivery. Patients required a median of one mobilization cycle. No VOCs were reported post-engraftment. BEAM-101 is manufactured using an advanced, largely automated process that has demonstrated consistently high yields and viability, enabling successful manufacturing for all patients in the BEACON clinical trial as of the data cut-off. A summary of the results from the ongoing clinical study is provided below.
0 · Reply
JonnyBGood12345
JonnyBGood12345 Jun. 12 at 11:40 AM
$BEAM I'm in Beam for the long haul. In my long term account
0 · Reply
DeerHunter55
DeerHunter55 Jun. 9 at 5:09 AM
$CRSP $NTLA $BEAM $EDIT $CRBU Get ready for today!!!
2 · Reply
roger120
roger120 Jun. 7 at 5:13 PM
$VERV $NTLA $BEAM $CRSP If true this field is going to explode.
1 · Reply
Gladiator007
Gladiator007 Jun. 7 at 12:19 PM
$VERV,$NTLA ,$BEAM ,$CRSP https://www.biospace.com/fda/rfk-jr-joins-deputies-in-voicing-support-for-regulatory-flexibility-for-cell-and-gene-therapies
1 · Reply
Jess_Inv
Jess_Inv Jun. 6 at 6:33 PM
$BEAM Nice job here!
0 · Reply
mankind1
mankind1 Jun. 6 at 5:57 PM
$BEAM wow! what happened here.
0 · Reply
Gladiator007
Gladiator007 Jun. 6 at 4:00 PM
$VERV , $NTLA ,$BEAM ,$TMDX My bio portfolio is doing great. Not looking to sell any for couple of months at the least
5 · Reply